Thyroid Carcinoma, Version 2.2014

View More View Less
  • 1 From Memorial Sloan Kettering Cancer Center; Dana-Farber/Brigham and Women’s Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Washington/Seattle Cancer Care Alliance; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; UCSF Helen Diller Family Comprehensive Cancer Center; Fox Chase Cancer Center; University of Michigan Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Huntsman Cancer Institute at the University of Utah; Stanford Cancer Institute; City of Hope Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Roswell Park Cancer Institute; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; Moffitt Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Vanderbilt-Ingram Cancer Center; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute; Duke Cancer Institute; The University of Texas MD Anderson Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; and National Comprehensive Cancer Network.
Restricted access

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on “Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer” was added to the NCCN Guidelines to assist with using these novel targeted agents.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 205 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 580 382 23
PDF Downloads 122 107 16
EPUB Downloads 0 0 0